[
    [
        {
            "time": "2018-02-13",
            "original_text": "Health Care Sector Update for 02/13/2018: ABC,WBA,LLY,BDX,DARE",
            "features": {
                "keywords": [
                    "Health Care",
                    "Sector Update",
                    "ABC",
                    "WBA",
                    "LLY",
                    "BDX",
                    "DARE"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 02/13/2018: ABC,WBA,LLY,BDX,DARE",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-02-13",
            "original_text": "Health Care Sector Update for 02/13/2018: DARE,LLY,BDX",
            "features": {
                "keywords": [
                    "Health Care",
                    "Sector Update",
                    "DARE",
                    "LLY",
                    "BDX"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 02/13/2018: DARE,LLY,BDX",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-02-14",
            "original_text": "Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 14, 2018",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Ex-Dividend",
                    "LLY"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 14, 2018",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-02-13",
            "original_text": "Health Care Sector Update for 02/13/2018: JNJ, PFE, ABT, MRK, AMGN, ABC, GNC, LLY, DARE, HCM, CLLS, BDX",
            "features": {
                "keywords": [
                    "Health Care",
                    "Sector Update",
                    "JNJ",
                    "PFE",
                    "ABT",
                    "MRK",
                    "AMGN",
                    "ABC",
                    "GNC",
                    "LLY",
                    "DARE",
                    "HCM",
                    "CLLS",
                    "BDX"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 02/13/2018: JNJ, PFE, ABT, MRK, AMGN, ABC, GNC, LLY, DARE, HCM, CLLS, BDX",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-02-13",
            "original_text": "Eli Lilly's Taltz meets primary endpoint in late-state trial for AS treatment",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Taltz",
                    "primary endpoint",
                    "trial",
                    "AS treatment"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly's Taltz meets primary endpoint in late-state trial for AS treatment",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-02-13",
            "original_text": "Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)",
            "features": {
                "keywords": [
                    "Lilly",
                    "Positive",
                    "Top-Line",
                    "Phase 3",
                    "Taltz",
                    "Ankylosing Spondylitis"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-02-13",
            "original_text": "Eli Lilly: Taltz Phase 3 Study Meets Endpoints To Treat Ankylosing Spondylitis",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Taltz",
                    "Phase 3",
                    "Endpoints",
                    "Ankylosing Spondylitis"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly: Taltz Phase 3 Study Meets Endpoints To Treat Ankylosing Spondylitis",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]